The Medicines Co. Offers Results of Phase 3 Trial of Cangrelor for Treatment of Patients Undergoing PCI
The Medicines Company (NASDAQ: MDCO) today announced results for its pivotal Phase 3 clinical trial of cangrelor, which is in development to prevent platelet activation and aggregation that leads to thrombosis in the acute care setting, including in patients undergoing percutaneous coronary intervention (PCI). Following the recommendation of the trial's Data Safety Monitoring Board (DSMB) in July 2012 to continue the protocol as planned, the CHAMPION PHOENIX trial completed enrollment in October 2012. After successful data lock, the data analysis revealed that the protocol defined primary composite efficacy endpoint of death, myocardial infarction, ischemia driven revascularization and stent thrombosis at 48 hours was met. Cangrelor demonstrated statistically significant improvement as compared to clopidogrel. Safety outcomes were similar to those observed in prior trials. The trial results are planned to be presented at a major upcoming scientific meeting. Commenting on the trial and its conduct, Dr. Robert A. Harrington, MD, Professor of Medicine and Chairman of Medicine at Stanford University and Co-Principal Investigator said: "The PHOENIX trial was designed with careful consideration of the prior studies to determine whether cangrelor is associated with improved ischemic outcomes compared with the usual treatment of oral clopidogrel. We are grateful to the many investigators around the world who enabled rapid enrollment and the collection of high quality data. We are pleased that the trial delivered such clear results."
"We are looking forward to presenting detailed results to the medical community as soon as the data are fully analyzed," said Dr. Deepak L. Bhatt, MD, MPH, Chief of Cardiology at VA Boston Healthcare System, Senior Physician at Brigham and Women's Hospital, Professor of Medicine at Harvard Medical School and Co-Principal Investigator of the CHAMPION Trials. Clive Meanwell MD, PhD, Chairman and Chief Executive Officer of The Medicines Company added that the Company expects to submit data both from the CHAMPION PHOENIX trial and from the BRIDGE trial in the USA and EU for regulatory review in 2013. "We believe that fast acting and rapidly reversible cangrelor may have an important role to play both in patients undergoing PCI and in patients who need to discontinue oral P2Y12 inhibitors prior to surgery," he said.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.